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Background: To investigate the effectiveness of amniotic membrane transplantation (AMT) 
on improving the outcomes of trabeculectomy in primary open-angle glaucoma (POAG).
Methods: Fifty-nine eyes affected by primary open-angle glaucoma were enrolled in this pro-
spective randomized study. Thirty-two eyes underwent amnion-shielded trabeculectomy (study 
group) and 27 eyes underwent trabeculectomy without any antimetabolites (control group). 
Success was defined as intraocular pressure (IOP) ,21 mmHg without any medications at 
24 months follow-up. The two groups were compared in terms of IOP, bleb morphology, bleb 
survival and risk of failure, glaucoma medications, and complications.
Results: There was no statistically significant difference in terms of postoperative IOP between 
the two groups and at 24 months median IOP was 15.5 mmHg for the AMT group and 16 mmHg 
for the control group. IOP postoperative reduction was 8 mmHg for the AMT group versus 
6 mmHg for the non AMT group (P = 0.276). Two patients from the study group developed 
IOP .21 mmHg in contrast to seven patients from the classic trabeculectomy group. The study 
group had 61.0% less risk of developing IOP .21 mmHg (P = 0.203). No major complications 
in the AMT group were observed. AMT blebs were diffuse with mild vascularization.
Conclusion: In patients with POAG, AMT showed favorable effects on bleb survival, 
however data failed to provide firm evidence that AMT could be used as a routine procedure 
in trabeculectomy.
Keywords: amniotic membrane, trabeculectomy, primary open-angle glaucoma, glaucoma 
filtering bleb
Introduction
Fibrosis and scarring occurring at the subconjunctival space is the main reason for 
failure of the most established glaucoma filtration surgery (GFS).1 The introduction 
and widespread use of antiproliferative agents affecting fibroblast proliferation2 and 
apoptosis3 such as MM-C4–7 and 5-FU8–10 have improved surgical outcomes; neverthe-
less, their well-known complications mean that safer alternatives for fibrosis control 
are still needed.11–14 There are several events in the healing process that can potentially 
be modified such as: inflammation; fibrin formation; growth factors and cytokines; 
cellular proliferation; differentiation, apoptosis and migration; wound contraction; 
and angiogenesis.15 Several older and newer agents have been tested in vitro and in 
vivo such as cyclosporine, tranilast (N-[3′,4′]-dimethoxycinnamol) anthranilic acid,15 
suramin,16 ilomastat,17 Lerdelimumab Trabio CAT-15218 and many others19 but none 
of them have yet entered clinical practice.
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Moreover, it is known that fibroblast proliferation and 
  differentiation to myofibroblasts following surgical trauma at 
the site of trabeculectomy is promoted by tranforming growth 
factor β (TGF β), and in particular the isoform TGF β2 is one of 
the most potent scarring stimulators in the eye.20–22 Production 
of extracellular matrix by the activated fibroblasts leads to the 
formation of subconjunctival granular tissue23 followed by 
obstruction of the filtration site,24,25 hence targeting TGF-β 
appears promising in reducing postoperative fibrosis.
Human amniotic membrane, known for its antifibrotic, 
anti-inflammatory and anti-angiogenic properties, suppresses 
transforming growth factor β (TGF β)26 and has been tested as 
an adjuvant in high-risk GFS,27,28 as a substrate for the repair 
of leaking glaucoma blebs,29 and for the management of tube 
exposure following tube shunt surgery.30 Although results 
from previous clinical and experimental studies of amniotic 
membrane transplantation in trabeculectomy have been prom-
ising, it remained unclear whether amniotic membrane could 
be used as a routine procedure for the prevention of fibrosis in 
GFS. For this purpose we carried out this prospective baseline 
study evaluating the effectiveness of AMT in trabeculectomy 
for the treatment of primary open-angle glaucoma (POAG). 
Characteristics of the amniotic membrane are discussed.
Methods
Sixty-one consecutive patients (70 eyes) with primary 
open glaucoma were assessed for eligibility to participate 
in the study. Five patients refused and six did not meet the 
inclusion criteria. Figure 1 shows the flow of the patients in 
the study. After informed consent was obtained, 59 eyes of 
50 patients were randomized in two groups. The first group 
(study group) consisted of 27 eyes that received amniotic 
membrane transplantation at the trabeculectomy site and the 
second group (control group) consisted of 32 eyes that under-
went standard trabeculectomy without any antimetabolites.
Inclusion criteria were the presence of POAG and at 
least one of the following: unsatisfactory target intraocular 
pressure (IOP) control with topical antiglaucoma treatment; 
optic nerve damage progression on two consecutive visual 
field tests and increase of cup-to-disk ratio in a period of 
24 months; allergy to topical agents; or poor compliance. 
Exclusion criteria were: any other type of glaucoma; only-eye 
patients; past or present anterior segment pathology coexis-
tence (apart from cataract); and previously failed glaucoma 
filtration surgery. The study design was according to the 
Declaration of Helsinki.
Human amniotic membranes were prepared as previ-
ously described.29,31 Human placenta was obtained under 
sterile condition shortly after cesarean section when Human 
Immunodeficiency Virus, Hepatitis B and C virus, syphilis, 
and Creutzfeldt–Jacob disease had been excluded with 
serological testing. Under a lamellar flow hood, the placenta 
was washed free of blood clots with sterile physiologic 
saline solution containing 50 mg/mL penicillin, 50 mg/mL 
Assessed for eligibility
(n = 70 eyes)
6 refused to
participate
5 did not meet
inclusion criteria
Randomization 45:55
(n = 59)
32 eyes underwent
standard
trabeculectomy
(control group)
27 eyes received
amniotic membrane
transplantation
(study group)
5 eyes lost to follow-up
(censored at 6
months post-op)
2 eyes lost to follow-up
(censored at 6
months post-op)
22 eyes completed
follow-up
30 eyes completed
follow-up
Figure 1 Flow chart showing the progression of patients in the study.
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streptomycin, 100 mg/mL neomycin, 2.5 mg/mL ampho-
tericin, and subsequently the amnion was separated from 
the rest of the chorion with blunt dissection. The amniotic 
membrane was then placed on to nitrocellulose paper with 
the epithelial/basement membrane facing up, cut into rect-
angular pieces of 3 × 3 cm and stored at -80°C in sterile 
vials containing Dulbecco’s Modified Eagle’s solution and 
glycerol at a ratio of 1:1. The membranes for use were left 
to defrost for 10 minutes before surgery at operating theatre 
temperature and washed twice with balanced salt solution 
before transplantation.
Surgery was performed by two surgeons under inferior 
nasal fornix sub-Tenon’s anesthesia consisting of lidocaine 
and marcaine at a ratio of 1:4. The surgical technique was 
as follows. A fornix-based superior conjunctival peritomy 
was performed followed by cautery and thorough cleaning 
of the scleral surface. A 3 × 4 mm scleral flap was prepared 
and anterior chamber paracentesis was done followed by 
sclerectomy with Vannas scissors. Iridectomy was performed 
with iris scissors and the scleral flap secured with 2 8.0 nylon 
sutures. Once good filtration was assured, one rectangular 
piece of amniotic membrane measuring approximately 
5 × 5 mm was prepared and positioned over the scleral flap 
with the matrix side facing the scleral surface. No sutures 
were used to secure the membrane. Tenon’s capsule and 
conjunctiva were positioned over the membrane and closed 
with interrupted 7.0 Vicryl sutures, taking extra care not to 
fold the amniotic membrane. The paracentesis tract was used 
to inject balanced salt solution into the anterior chamber to 
confirm aqueous flow in the newly formed bleb and check 
for leakage. Subconjunctival injection of betamethasone 1% 
and cefuroxime 125 mg was administered in the inferior   
fornix.
The eye patch was removed the next morning and eyes 
were examined at 1 day, 1 week, 2 weeks, 1 month, 2 months, 
and every 6 months thereafter for a minimum of 2 years 
follow-up. Additional visits were scheduled at the discretion 
of the operating surgeon. The postoperative regime was iden-
tical for both groups and consisted of topical dexamethasone 
1% and tobramycin 6 times daily for 1 month followed by 
a tapering schedule. Visual acuity, IOP, slit-lamp examina-
tion, and bleb characterization in terms of area, vascularity, 
and height based on the principles of the Moorfields Bleb 
Grading System was performed at each visit.
Results are given as median ± inter quartile range (IQR) 
except where indicated. Statistical evaluation between cat-
egorical variables and type of surgery was performed using 
Fisher’s Exact Test. A nonparametric Mann–Whitney test was 
used for comparison of continuous quantitative variables. 
The Wilcoxon matched-pairs signed ranks test was used for 
the statistical analysis of number of medications before and 
after surgery. Cox proportional hazards model and Kaplan–
Meier analysis and curves were performed. A P value less 
than 0.05 was considered statistically significant. Success 
was defined as IOP ,21 mmHg without any medications at 
any stage of the follow-up. Primary outcome measures were 
IOP, and functionality and morphology of the bleb. The sec-
ondary outcome measure was the reduction of antiglaucoma 
medications. Eyes lost from follow-up have been included 
in the analysis until they stopped attending the scheduled 
postoperative visit and then censored from the study (right 
censoring). Intraoperative and postoperative complications 
were reported. All statistical analyses were performed with 
SPSS (v 16.0 for Windows; SPSS, Inc, Chicago, IL).
Results
A total of 59 eyes underwent statistical analysis, 27 of which 
received amniotic membrane transplantation (amniotic–study 
group, 45.7%) and 32 underwent trabeculectomy with-
out any antifibrotic agents (nonamniotic–control group, 
54.3%). Table 1 shows demographic and principal clinical 
  characteristics. At 24 months follow-up, two patients from 
the study group and seven from the control group devel-
oped IOP .21 mmHg and had to start topical antiglaucoma 
  treatment. There was no statistical difference in the number of 
medications between study and control group before surgery 
(P = 0.889) or after surgery (P = 0.302).
Figure 2 provides median intraocular pressures variation 
pre- and post-op for each group up to 24 months follow-up. 
There were no differences between the two groups (study 
group median IOP at 24 months was 15.5 mmHg vs 
16 mmHg of the control group).
Table 2 shows the reduction of intraocular pressure for 
each group and the comparison between amniotic and non-
amniotic eyes. At the end of the follow-up, IOP reduction in 
the study group was 8 mmHg (median) and 6 mmHg in the 
control group (P = 0.276). The P value at each visit demon-
strates that there was no statistically significant difference 
between the two groups.
The number of postoperative medications decreased sig-
nificantly in both groups (P , 0.001) (Table 3). Two patients 
in the amniotic group (9%) and six patients in the nonamni-
otic group (20%) needed topical antiglaucoma treatment.
The risk of developing IOP $21 mmHg based on the 
type of surgery was calculated with the Cox Proportional 
Hazards Model. In 24 months follow-up, eyes that underwent 
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amnion shielded trabeculectomy had 61.6% less risk of 
IOP $21 mmHg compared to eyes that underwent trabeculec-
tomy without amniotic membrane   transplantation. However 
the P value was not statistically significant (P = 0.233). 
Figure 3 gives the estimated survival probabilities of 
IOP $21 mmHg in the two groups.
With regards to bleb morphology, six eyes in the study 
group (22%) had particularly elevated blebs at 2 weeks 
(Figure 4A) in contrast to only one (3%) of the control 
group. All the amniotic blebs decreased in height and 
became diffuse with mild vascularization at 1 month post-op 
(Figure 4B and C). Only one eye from the study group had 
subconjunctival blood at 2 weeks, which resolved completely 
at 1 month. The same eye, at the end, developed a nonvascu-
larized bleb with a cystic wall in the presence of a very good 
IOP control. At 6 months post-op, five of the 27 study eyes 
(18%) had a flat mildly vascularized bleb, 15 eyes (55.5%) 
had a grade 2 bleb height with normal vascularization, and 
one bleb (3.7%) was encysted (Figure 5). There were no thin 
avascular blebs. Of the control group, eight eyes (25%) had 
a flat bleb, 20 eyes (62.5%) had a grade 2 bleb with normal 
vascularization, and four eyes (12.5%) had encysted blebs.
Postoperative interventions included laser suture 
lysis in one eye of the nonamniotic group that developed 
IOP .21 mmHg and subsequently the IOP normalized 
promptly. Three AMT eyes (11%) and six control group 
eyes (18.7%) presented with shallow anterior chambers the 
first day post-op, which deepened at the end of the first week 
without intervention.
In terms of complications there were no cases of 
endophthalmitis. One eye of the amniotic group had diffuse 
dot blot retinal hemorrhages at 1 week post-op probably 
related to intraoperative hypotony, which resolved spontane-
ously at 1 month and one eye presented with anterior chamber 
fibrin 48 hours following surgery due to poor compliance 
because the patient did not instill steroids at all. The fibrin 
resolved promptly following subconjunctival injection of 
steroids. There were three eyes from the control group that 
developed limited choroidal detachment not threatening the 
macula or affecting vision, which fully resolved by the end 
of the first 4 weeks. There were no leaking blebs and no eyes 
needed urgent reintervention.
Visual acuity (VA) remained essentially unchanged 
for the first 6 months post-op and there was no difference 
between the two groups in terms of cataract progression 
(Table 4). However, from the sixth month until the end 
of the follow-up some of the patients had to be listed for 
cataract surgery, therefore VA was excluded from further 
statistical analysis.
Table 1 Demographics and principal clinical characteristics of amniotic and nonamniotic groups
Nonamniotic 
N (%)
Amniotic 
N (%)
P–value
Gender 0.183
  Female 16 (50.0) 8 (29.6)
  Male 16 (50.0) 19 (70.4)
iOP $ 21 after operation 0.16
  no 25 (78.1) 25 (92.6)
  Yes 7 (21.9) 2 (7.4)
Median (IQR)
Age (years) 71.5 (67.0, 76.0) 70.0 (63.0, 80.0) 0.755
Mean (min, max)
no of medicines before operation 2.67 (1, 4) 2.64 (1, 4) 0.889
no of medicines after operation 0.33 (0, 3) 0.18 (0, 3) 0.302
Reduction in no of medicines after operation 2.33 (0, 4) 2.45 (0, 4) 0.766
Abbreviations: iOP, intraocular pressure; iQR, median ± inter quartile range.
Operation
0
5
1
0
1
5
2
0
2
5
I
O
P
 
(
m
m
H
g
)
06 12 18 24
Months since operation
Amniotic
Operation
Non-amniotic
Figure 2 Plot of the intraocular pressure over time.
Notes: Bars indicate iQR. There was no statistical difference between the two 
groups at any time during the follow-up.
Abbreviations: iQR, median ± inter quartile range; iOP, intraocular pressure.
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Discussion
Healing response after glaucoma filtration surgery is the 
main determinant of surgical failure, therefore wound healing 
modulation appears to be the key element in order to improve 
trabeculectomy outcomes.
The amniotic membrane is the innermost layer of the 
fetal membranes and has multiple properties26 that might 
be beneficial in the process of wound healing modulation in 
glaucoma filtration surgery such as angiogenesis suppres-
sion, good epithelization, no host rejection, high hydraulic 
conductivity, low healing response,1 and more importantly 
it downregulates the TGF-β2.32 It was Fujishima et al who 
first suggested the use of AMT in GFS in 199828 followed 
by Barton et al1 who demonstrated improved trabeculec-
tomy survival rate in experimental glaucoma surgery and 
launched the idea of AM transplantation in trabeculectomy. 
Droslum et al used a double sheet of amniotic membrane 
impregnated in MM-C in nine patients with refractory 
glaucoma with encouraging results but no control group,27 
similarly to Sheha et al who found significant advantage in 
using a single layer of AM and MM-C under the scleral flap 
compared to only MM-C in a prospective study of 37 eyes 
with refractory glaucoma.33 Zheng found no difference in 
trabeculectomy with neither AM or MM-C in a prospective 
study of 48 eyes34 whereas Eliezer used a folded membrane 
over the sclera and did not notice a statistically significant 
difference in terms of IOP between classic and amnion 
shielded trabeculectomy at 12 months follow-up in 32 eyes 
with POAG.35 In further experiments amniotic membrane 
was shown to be less effective than MMC36 and octreotide37 
in reducing fibroblast proliferation in GFS but still with a 
significant antifibrotic effect.
This was a prospective randomized study assessing the 
efficacy of amniotic membrane transplantation in trabeculec-
tomy with, to the best of our knowledge, the longest follow-up 
period (24 months) and the largest number of participating 
eyes (59 eyes). In order to assess a therapeutic intervention 
it is essential to compare efficacy and complications against 
a standard procedure. Trabeculectomy, almost 40 years 
since its introduction,38 remains the gold standard in GFS for 
POAG, and we chose patients with POAG because it is the 
most common type of glaucoma. We set IOP ,21 mmHg as 
Table 2 Reduction of intraocular pressure pre- and post-op for each group up to 24 months follow-up and comparison between the 
two groups
Nonamniotic 
median (IQR)
Amniotic 
median (IQR)
P-value
1 day after operation -12.0 (-16.0, -9.5) -13.0 (-16.0, -11.0) 0.609
2 months after operation -7.0 (-10.0, -6.0) -8.0 (-10.0, -6.0) 0.603
6 months after operation -7.0 (-10.0, -4.0) -7.5 (-10.0, -6.0) 0.758
12 months after operation -7.0 (-9.0, -5.0) -7.5 (-9.0, -5.5) 0.668
18 months after operation -7.0 (-9.0, -5.0) -8.0 (-10.0, -6.0) 0.524
24 months after operation -6.0 (-8.5, -4.5) -8.0 (-9.0, -6.0) 0.276
Note: *Statistically significant at 0.0083 level (after Bonferroni correction for multiple comparisons).
Abbreviation: iQR, median ± inter quartile range.
Table 3 number of topical antiglaucoma medications before and 
after surgery for each group
No of medicines Before operation 
N (%)
After operation 
N (%)
Nonamniotic
0 0 (0) 26 (81.2)
1 1 (3.1) 3 (9.3)
2 12 (37.5) 2 (6.2)
3 15 (46.8) 1 (3.1)
4 4 (12.5) 0 (0)
Amniotic
0 0 (0) 25 (92.5)
1 1 (3.7) 1 (3.7)
2 9 (33.3) 0 (0)
3 14 (51.8) 1 (3.7)
4 3 (11.1) 0 (0)
Note: P-value (Wilcoxon matched-pairs signed-ranks test): ,0.001.
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Figure 3 Kaplan–Meier filtration surgery survival curve.
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the endpoint in order to be comparable with the majority of 
the published surgical trials of trabeculectomy survival and 
did not use any antimetabolites because the aim was a base-
line study of the amniotic membrane in GFS. Demographics 
were similar in both study and control groups and the pre-
operative intraocular pressures and number of medications 
did not differ significantly. We positioned the amniotic layer 
over the scleral flap based on the assumption that fibrosis 
responsible for bleb failure is primarily formed at the subcon-
junctival space. This is the first study where the amnion was 
not sutured, resulting in shorter operative time and potentially 
fewer intraoperative   complications. The surgical technique 
followed by the two surgeons was the same in order to reduce 
intra-observer bias.
Results show that postoperative IOP levels were arith-
metically lower in the amnion group but never reached 
statistically significant levels throughout the 24 months of 
follow-up. Reduction of IOP was greater in the amniotic 
group and at 24 months the difference between study and 
control group reached 2 mmHg, however the P value was 
again not significant. Of better value to the comparison 
between the two groups seems to be the survival curve and 
the risk of developing IOP $21 mmHg. In fact the AMT 
filtration procedure showed longer survival in terms of IOP 
reduction (Figure 3) and 61% less risk of failure compared 
to the standard procedure. Unfortunately the P value failed to 
reach statistical significance and, based on the risk value, we 
believe this is probably due to the relatively small size of the 
study population rather than ineffectiveness of the AMT.
Bleb morphology showed more diffuse and mildly 
vascularized blebs in the AMT group, compared to flatter 
blebs in the control group. This could be associated with a 
better bleb function with a more diffuse area of drainage 
and less risk of cystic, thin-walled blebs that we observe 
when treating with antimetabolites. The aforementioned 
is supported by the anti-scarring properties of the AM. No 
major intra- or postoperative complications were noted 
and no re-operations for leakage were needed, thus AMT 
proved safe and easy to perform. Patients did not complain 
of dysesthetic blebs since the initially elevated AMT blebs 
normalized in height 4 weeks following surgery, in agree-
ment with previous observations in rabbits that AM dissolves 
in approximately 1 month.39
The unequal number of study and control eyes is an obvi-
ous weakness of this study and this is because in the first 
year of the study, five patients from the AMT group and two 
from the control group were lost to follow-up and therefore 
included in the first 6 months data analysis only. They were 
excluded thereafter, using right censoring in order to avoid 
major bias in the long-term results since those were, accord-
ing to our opinion, of major importance. Furthermore we 
used one single layer of amniotic membrane in contrast to 
previous reports of folded or double layer of AM, because we 
did not have strong evidence to support a synergistic effect 
of more layers of AM.
Like any other biological substrate transplantation, 
amniotic membrane transplantation has a potential danger 
of spreading viruses and bacteria. The risk of infections is 
Figure 4 Appearance of elevated amnion shielded trabeculectomy bleb at 1 week post-op (A). Amniotic group blebs at 1 month post-op. The blebs are diffuse, with mild 
vascularization (B and C).
Figure 5 Cystic bleb of the amniotic group at 2 weeks post-op. The bleb remained 
dysfunctional throughout the follow-up.
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minimized if adequate donor screening and serological test-
ing is performed and it is imperative to respect the 6 months 
window period and retest the donor before the amnion is 
used. Moreover, it is recommended that amnion for use in 
ocular surgery should be obtained from elective cesarean 
deliveries.40
With this prospective randomized study we tried to 
investigate the usefulness of AMT in trabeculectomies for 
the treatment of primary open glaucoma. In conclusion, the 
aforementioned outcomes were suggestive of a favorable 
effect of the AM on wound healing and bleb survival; nev-
ertheless our data do not provide firm evidence that AMT 
should be used as a routine procedure in the surgical treat-
ment of POAG.
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